Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation ofschizophrenia

Neuropsychopharmacology

Volumn 28, Issue 1, 2003, Pages 182-192

  Casey, Daniel E ^a   Daniel, David G ^b,c   Wassef, Adel A ^d   Tracy, Katherine A ^e,f   Wozniak, Patricia ^e   Sommerville, Kenneth W ^e  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c Bioniche Development   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e ABBOTT LABORATORIES   (United States)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Divalproex; Olanzapine; Psychosis; Risperidone; Schizophrenia

Indexed keywords

BENZODIAZEPINE DERIVATIVE; DRUG DERIVATIVE; NEUROLEPTIC AGENT; OLANZAPINE; PIRENZEPINE; RISPERIDONE; TRANQUILIZER; VALPROIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FEMALE; HUMAN; MALE; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGED; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PIRENZEPINE; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; VALPROIC ACID;

EID: 0037209034     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/sj.npp.1300023     Document Type: Article

References (36)

1. Barnes TRE (1989). A rating scale for drug-induced akathisia.Br J Psychiatry154: 672-676.
2. Benes FM, Berretta S (2001). GABAergic interneurons: Implications for understanding schizophrenia and bipolar disorder.Neuropsychopharmacology25: 1-27.
3. Calandre EP, Rodriguez-Lopez C, Blazquez A, Cano D (1991). Serum lipids, lipoproteins, and apolipoproteins A and B inepileptic patients treated with valproic acid, carbamazepine, orPhenobarbital.ActaNeurolScand83: 250-253.
4. Chong S-A, Tan C-H, Lee -L, Liow P-H (1998). Augmentation of risperidone with valproic acid [letter].J Clin Psychiatry59: 430.
5. Citrome L, Levine J, Allingham B (2000). Changes in use of valproate and other mood stabilizers for patients with schizo-phrenia from 1994 to 1998.PsychiatrServ51: 634-638.
6. Conley RR, Mahmoud R (2001). A randomized double-blind study of risperidone and olanzapine in the treatment of schizophreniaor schizoaffective disorder.Am J Psychiatry158: 765-774.
7. Dose M, Hellweg R, Yassouridis A, Theison M, Emrich HM (1998). Combined treatment of schizophrenic psychoses with haloperidol and valproate.Pharmacopsychiatry31: 122-125.
8. Edgell ET, Andersen SW, Johnstone BM, Dulisse B, Revicki D, Breier A (2000). Olanzapine versus risperidone.A prospectivecomparison of clinical and economic outcomes in schizophrenia.Pharmacoeconomics18: 567-579.
9. Egan MF, Hyde TM (1999). Schizophrenia: neurobiology.Kaplan & Sadock’s Comprehensive Textbook of Psychiatry.LippincottWilliams& Wilkins: Philadelphia.
10. Eiris JM, Lojo S, Del Rio MC, Novo I, Bravo M, Pavon P (1995). Effects of long-term treatment with antiepileptic drugs on serumlipid levels in children with epilepsy.Neurology45: 1155-1157.
11. First MB, Spitzer RL, Gibbon M, Williams JBW (1999).Research Version of the Structured Clinical Interview (SCID) for DSM-IVAxis 1 Disorders, Modified for Abbott Protocol M99-010.NewYork State Psychiatric Institute: New York.
12. Franzoni E, Govoni M, D’Addato S, Gualandi S, Sangiorgi Z, Descovich GC (1992). Total cholesterol, high-density lipoproteincholesterol, and triglycerides in children receiving antiepilepticdrugs.Epilepsia33: 932-935.
13. Garbutt JC, van Kammen DP (1983). The interaction between GABA and dopamine: Implications for schizophrenia.SchizophrBull9: 336-353.
14. Gidal B, Spencer N, Maly M, Pitterle M, Williams E, Collins M (1994). Valproate-mediated disturbances of hemostasis: Relationship to dose and plasma concentration.Neurology44: 1418-1422.
15. Goden Y, Heiner L, Mark J (1969). Effects of di-n-propylacetate, an anticonvulsant compound, on GABA metabolism.J Neurochem16: 69-73.
16. Gundurewa VM, Beckman H, Zimmer R, Ruther E (1980). Effect of valproic acid on schizophrenic syndromes.Arzneimittelforschung30: 1212-1213.
17. Guy W (1976).ECDEU Assessment Manual for Psychopharmacol-ogy, publication no. ADM 76-336.US Department of Health, Education and Welfare: Rockville, MD.
18. Heldenberg D, Harel S, Holtzman M, Levtow O, Tamir I (1983). The effect of chronic anticonvulsant therapy on serum lipids andlipoproteins in epileptic children.Neurology33: 510-513.
19. Hessinger B, Normann C, Langosch JM, Klose P, Berger M, Walden J (1999). Effects of carbamazepine and valproate on haloperidolplasma levels and on psychopathologic outcome in schizophre-nic patients.J ClinPsychopharmacol19: 310-315.
20. Horie S, Suga T (1985). Enhancement of peroxisomalbetaoxidation in the liver of rats and mice treated with valproic acid.BiochemPharmacol34: 1357-1362.
21. Kasper S, Jones M, Duchesne IRODOS Investigator Group (2001). Risperidone Olanzapine Drug Outcomes Studies inSchizophrenia (RODOS)* Health economic results of aninternational naturalistic study.IntClin Psychopharmacol16:189-196.
22. Kay SR, Fiszbein A, Opler LA (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.Schizophr Bull13:261-276.
23. Ko GN, Korpi ER, Freed WJ, Zalcman SJ, Bigelow LB (1985). Effect of valproic acid on behavior and plasma amino acid concentra-tions in chronic schizophrenic patients.Biol Psychiatry20: 209-215.
24. Meltzer HY, Dai J, Ichikawa J (2001).Valproic acid, an antic-onvulsant, mood stabilizer, potentiates antipsychotic drugs-induced dopamine release in rat medial prefrontal cortex but not nucleus accumbens [abstract].SocNeurosciAbstrvol 27, Program no. 572.14.
25. Moringo A, Martin J, Gonzalez S, Mateo I (1989). Treatment of resistant schizophrenia with valproate and neuroleptic drugs.Hillside J Clin Psychiatry11: 199-207.
26. Preisendorfer U, Zeise ML, Klee MR (1987). Valproate enhances inhibitory postsynaptic potentials in hippocampal neurons invitro.Brain Res435: 213-219.
27. Reynolds GP, Zhang ZJ, Beasley CL (2001). Neurochemical correlates of cortical GABAergic deficits in schizophrenia:Selective losses of calcium binding protein immunoreactivity.Brain Res Bull55: 579-584.
28. Seeman P (1987). Dopamine receptors and the dopamine hypothesis of schizophrenia.Synapse1: 133-152.
29. Simpson GM, Angus JW (1970). A rating scale for extrapyramidal side effects.ActaPsychiatricaScandSupp212: 11-19.
30. Spina E, Avenoso A, Facciola G, Salemi M, Scordo MG, Giacobello T (2000). Plasma concentrations of risperidone and 9-hydro-xyrisperidone: Effect of comedication with carbamazepine orvalproate.Ther Drug Monit22: 481-485.
31. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley Jr C (1997).Double-blind comparison of olanzapineversus risperidone in the treatment of schizophrenia and otherpsychotic disorders.J ClinPsychopharmacol17: 407-418.
32. Volk D, Austin M, Pierri J, Sampson A, Lewis D (2001). GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia:Decreased expression in a subset of neurons.Am J Psychiatry158: 256-265.
33. Wassef AA, Dott SG, Harris A, Brown A, O’Boyle M, Meyer WJ (1999). Critical review of GABA-ergic drugs in the treatment ofschizophrenia.J ClinPsychopharmacol19: 222-232.
34. Wassef AA, Dott SG, Harris A, Brown A, O’Boyle M, Meyer WJ (2000).Randomized, placebo-controlled pilot study of dival-proex sodium in the treatment of acute exacerbations of chronicschizophrenia.J ClinPsychopharmacol20: 357-361.
35. Wassef AA, Hafiz NG, Hampton D, Molloy M (2001). Divalproex sodium augmentation of haloperidol in hospitalized patientswith schizophrenia: Clinical and economic implications.J ClinPsychopharmacol21: 21-26.
36. Wassef A, Watson DJ, Morrison P, Bryant S, Flack J (1989). Neuroleptic-valproic acid combination in treatment ofpsychotic symptoms: A three-case report.J ClinPsychopharma-col9: 45-48.